Possis to start cerebrovascular stroke trial:
This article was originally published in Clinica
Possis Medical has received approval from the FDA to begin US clinical trials of its clot-busting AngioJet system in the treatment of severe acute cerebrovascular stroke. The Phase I trial will enrol 30 patients at six hospitals, said the Minneapolis, Minnesota-based company. The AngioJet device is already approved in the US for removing blood clots in coronary arteries and bypass grafts and is currently being assessed as a treatment for carotid stroke (see Clinica No 844, p 16).